On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the grant of a preliminary injunction by the Northern District of ...

Addressing a preliminary injunction in patent litigation related to the Biologics Price Competition and Innovation Act (BPCIA), the US Court ...

February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...

(MENAFN- GlobeNewsWire - Nasdaq) SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company ...

Regeneron offered a price concession that lowered EYLEA’s selling price; (4) because retina practices were sensitive to higher prices when using a credit card to purchase anti-VEGF medications ...

Regeneron offered a price concession that lowered EYLEA’s selling price; (4) because retina practices were sensitive to higher prices when using a credit card to purchase anti-VEGF medications, ...

The losses were primarily due to the patent expiration of Regeneron's key drug Eylea, its VEGF-inhibiting eye disease drug, indicated for "wet" advanced macular degeneration ("AMD"), and diabetic ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) faces ongoing competitive pressure in the anti-VEGF category, particularly affecting EYLEA sales. The company anticipates continued market dynamics that ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...